COVID-19 Gives Gilead A Down Quarter, But Guidance Boosted By Remdesivir

 
• By Mandy Jackson
  
Second quarter
Gilead had $5.07bn in second quarter 2020 sales, down 10% year-over-year • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business